An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma.
GL261
Glioblastoma
HSV-1
Immunotherapy
Oncolytic virus
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
01
08
2024
accepted:
04
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Glioblastoma (GBM) is the most frequent and aggressive brain tumor in adults with the lowest survival rates five years post-diagnosis. Oncolytic viruses (OVs) selectively target and damage cancer cells, and for this reason they are being investigated as new therapeutic tools also against GBM. An oncolytic herpes simplex virus type 1 (oHSV-1) with deletions in the γ34.5 neurovirulence gene and the US12 gene, expressing enhanced green fluorescent protein (EGFP-oHSV-1) as reporter gene was generated and tested for its capacity to infect and kill the murine GL261 glioblastoma (GBM) cell line. Syngeneic mice were orthotopically injected with GL261cells. Seven days post-implantation, EGFP-oHSV-1 was administered intratumorally. Twenty-one days after parental tumor challenge in the opposite brain hemisphere, mice were sacrified and their brains were analysed by immunohistochemistry to assess tumor presence and cell infiltrate. oHSV-1 replicates and induces cell death of GL261 cells in vitro. A single intracranial injection of EGFP-oHSV-1 in established GL261 tumors significantly prolongs survival in all treated mice compared to placebo treatment. Notably, 45% of treated mice became long-term survivors, and rejected GL261 cells upon rechallenge in the contralateral brain hemisphere, indicating an anamnestic antitumoral immune response. Post-mortem analysis revealed a profound modification of the tumor microenvironment with increased infiltration of CD4 + and CD8 + T lymphocytes, intertumoral vascular collapse and activation and redistribution of macrophage, microglia, and astroglia in the tumor area, with the formation of intense fibrotic tissue suggestive of complete rejection in long-term survivor mice. EGFP-oHSV1 demonstrates potent antitumoral activity in an immunocompetent GBM model as a monotherapy, resulting from direct cell killing combined with the stimulation of a protective adaptive immune response. These results open the way to possible application of our strategy in clinical setting.
Sections du résumé
BACKGROUND
BACKGROUND
Glioblastoma (GBM) is the most frequent and aggressive brain tumor in adults with the lowest survival rates five years post-diagnosis. Oncolytic viruses (OVs) selectively target and damage cancer cells, and for this reason they are being investigated as new therapeutic tools also against GBM.
METHODS
METHODS
An oncolytic herpes simplex virus type 1 (oHSV-1) with deletions in the γ34.5 neurovirulence gene and the US12 gene, expressing enhanced green fluorescent protein (EGFP-oHSV-1) as reporter gene was generated and tested for its capacity to infect and kill the murine GL261 glioblastoma (GBM) cell line. Syngeneic mice were orthotopically injected with GL261cells. Seven days post-implantation, EGFP-oHSV-1 was administered intratumorally. Twenty-one days after parental tumor challenge in the opposite brain hemisphere, mice were sacrified and their brains were analysed by immunohistochemistry to assess tumor presence and cell infiltrate.
RESULTS
RESULTS
oHSV-1 replicates and induces cell death of GL261 cells in vitro. A single intracranial injection of EGFP-oHSV-1 in established GL261 tumors significantly prolongs survival in all treated mice compared to placebo treatment. Notably, 45% of treated mice became long-term survivors, and rejected GL261 cells upon rechallenge in the contralateral brain hemisphere, indicating an anamnestic antitumoral immune response. Post-mortem analysis revealed a profound modification of the tumor microenvironment with increased infiltration of CD4 + and CD8 + T lymphocytes, intertumoral vascular collapse and activation and redistribution of macrophage, microglia, and astroglia in the tumor area, with the formation of intense fibrotic tissue suggestive of complete rejection in long-term survivor mice.
CONCLUSIONS
CONCLUSIONS
EGFP-oHSV1 demonstrates potent antitumoral activity in an immunocompetent GBM model as a monotherapy, resulting from direct cell killing combined with the stimulation of a protective adaptive immune response. These results open the way to possible application of our strategy in clinical setting.
Identifiants
pubmed: 39334370
doi: 10.1186/s12967-024-05650-5
pii: 10.1186/s12967-024-05650-5
doi:
Substances chimiques
Green Fluorescent Proteins
147336-22-9
enhanced green fluorescent protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
862Subventions
Organisme : Fondazione AIRC per la ricerca sul cancro ETS
ID : IG 2021-ID.26195
Organisme : Fondazione Celeghin
ID : Fondazione Celeghin
Organisme : Giancarlo Balbinot (Isopak Srl Unipersonale)
ID : Giancarlo Balbinot (Isopak Srl Unipersonale)
Informations de copyright
© 2024. The Author(s).
Références
Keller BA, Bell JC. Oncolytic viruses-immunotherapeutics on the rise. J Mol Med (Berl). 2016;94:979–91.
pubmed: 27492706
doi: 10.1007/s00109-016-1453-9
Campadelli-Fiume G, Petrovic B, Leoni V, Gianni T, Avitabile E, Casiraghi C, et al. Retargeting strategies for oncolytic herpes simplex viruses. Viruses. 2016;8:63.
pubmed: 26927159
doi: 10.3390/v8030063
pmcid: 4810253
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642–62.
pubmed: 26323545
doi: 10.1038/nrd4663
pmcid: 7097180
Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum Vaccin Immunother. 2018;14:839–46.
pubmed: 29420123
doi: 10.1080/21645515.2017.1412896
pmcid: 5893211
Lasner TM, Tal-Singer R, Kesari S, Lee VM, Trojanowski JQ, Fraser NW. Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice. J Neurovirol. 1998;4:100–5.
pubmed: 9531017
doi: 10.3109/13550289809113487
Cheng G, Feng Z, He B. Herpes simplex virus 1 infection activates the endoplasmic reticulum resident kinase PERK and mediates eIF-2alpha dephosphorylation by the gamma(1)34.5 protein. J Virol. 2005;79:1379–88.
pubmed: 15650164
doi: 10.1128/JVI.79.3.1379-1388.2005
pmcid: 544103
Orvedahl A, Alexander D, Tallóczy Z, Sun Q, Wei Y, Zhang W, et al. HSV-1 ICP34.5 confers neurovirulence by targeting the beclin 1 autophagy protein. Cell Host Microbe. 2007;1:23–35.
pubmed: 18005679
doi: 10.1016/j.chom.2006.12.001
Burgos JS, Serrano-Saiz E, Sastre I, Valdivieso F. ICP47 mediates viral neuroinvasiveness by induction of TAP protein following intravenous inoculation of herpes simplex virus type 1 in mice. J Neurovirol. 2006;12:420–7.
pubmed: 17162658
doi: 10.1080/13550280601009546
Liu BL, Robinson M, Han Z-Q, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10:292–303.
pubmed: 12595888
doi: 10.1038/sj.gt.3301885
Liu P, Wang Y, Wang Y, Kong Z, Chen W, Li J, et al. Effects of oncolytic viruses and viral vectors on immunity in glioblastoma. Gene Ther. 2022;29:115–26.
pubmed: 33191399
doi: 10.1038/s41434-020-00207-9
Reale A, Vitiello A, Conciatori V, Parolin C, Calistri A, Palù G. Perspectives on immunotherapy via oncolytic viruses. Infect Agent Cancer. 2019;14:5.
pubmed: 30792754
doi: 10.1186/s13027-018-0218-1
pmcid: 6371415
Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC. Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother. 2009;9:505–17.
pubmed: 19344302
doi: 10.1586/ern.09.9
pmcid: 3219506
Mortazavi SMJ, Mortazavi S a R, Paknahad M. Cancers of the brain and CNS: global patterns and trends in Incidence. J Biomed Phys Eng. 2018;8:151–2.
pubmed: 29732351
pmcid: 5928307
Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13.
pubmed: 29801989
doi: 10.1016/j.jocn.2018.05.002
Qi D, Li J, Quarles CC, Fonkem E, Wu E. Assessment and prediction of glioblastoma therapy response: challenges and opportunities. Brain. 2023;146:1281–98.
pubmed: 36445396
doi: 10.1093/brain/awac450
Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22:1073–113.
pubmed: 32328653
doi: 10.1093/neuonc/noaa106
pmcid: 7594557
Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res. 2022;41:142.
pubmed: 35428347
doi: 10.1186/s13046-022-02349-7
pmcid: 9013078
Medikonda R, Dunn G, Rahman M, Fecci P, Lim M. A review of glioblastoma immunotherapy. J Neurooncol. 2021;151:41–53.
pubmed: 32253714
doi: 10.1007/s11060-020-03448-1
Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell. 2017;31:326–41.
pubmed: 28292436
doi: 10.1016/j.ccell.2017.02.009
pmcid: 5424263
Hamad A, Yusubalieva GM, Baklaushev VP, Chumakov PM, Lipatova AV. Recent developments in glioblastoma therapy: oncolytic viruses and emerging future strategies. Viruses. 2023;15:547.
pubmed: 36851761
doi: 10.3390/v15020547
pmcid: 9958853
Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28:1630–9.
pubmed: 35864254
doi: 10.1038/s41591-022-01897-x
pmcid: 9388376
Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends Cancer. 2023;9:122–39.
pubmed: 36402738
doi: 10.1016/j.trecan.2022.10.003
Frampton JE. Teserpaturev/G47∆: first approval. BioDrugs. 2022;36:667–72.
Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med. 1995;1:938–43.
pubmed: 7585221
doi: 10.1038/nm0995-938
Xie XP, Laks DR, Sun D, Ganbold M, Wang Z, Pedraza AM, et al. Quiescent human glioblastoma cancer stem cells drive tumor initiation, expansion, and recurrence following chemotherapy. Dev Cell. 2022;57:32–e468.
pubmed: 35016005
doi: 10.1016/j.devcel.2021.12.007
pmcid: 8820651
Ausman JI, Shapiro WR, Rall DP. Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res. 1970;30:2394–400.
pubmed: 5475483
Szatmári T, Lumniczky K, Désaknai S, Trajcevski S, Hídvégi EJ, Hamada H, et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 2006;97:546–53.
pubmed: 16734735
doi: 10.1111/j.1349-7006.2006.00208.x
pmcid: 11159227
Gaston DC, Odom CI, Li L, Markert JM, Roth JC, Cassady KA, et al. Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS ONE. 2013;8:e81768.
pubmed: 24312353
doi: 10.1371/journal.pone.0081768
pmcid: 3842420
Reale A, Krutzke L, Cadamuro M, Vitiello A, von Einem J, Kochanek S, et al. Human monocytes are suitable carriers for the delivery of oncolytic herpes simplex virus type 1 in vitro and in a chicken embryo chorioallantoic membrane model of cancer. Int J Mol Sci. 2023;24:9255.
pubmed: 37298206
doi: 10.3390/ijms24119255
pmcid: 10253092
Jackson JW, Hall BL, Marzulli M, Shah VK, Bailey L, Chiocca EA, et al. Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment. Mol Ther Oncolytics. 2021;22:444–53.
pubmed: 34553031
doi: 10.1016/j.omto.2021.07.009
pmcid: 8430372
Nygårdas M, Paavilainen H, Müther N, Nagel C-H, Röyttä M, Sodeik B, et al. A herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunity. PLoS ONE. 2013;8:e64200.
pubmed: 23700462
doi: 10.1371/journal.pone.0064200
pmcid: 3659099
Agarwalla PK, Aghi MK. Oncolytic herpes simplex virus engineering and preparation. Methods Mol Biol. 2012;797:1–19.
pubmed: 21948465
doi: 10.1007/978-1-61779-340-0_1
Celesti F, Gatta A, Shallak M, Chiaravalli AM, Cerati M, Sessa F, et al. Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA. Front Immunol. 2023;14:1133177.
pubmed: 36993983
doi: 10.3389/fimmu.2023.1133177
pmcid: 10040613
Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14:2994–3006.
pubmed: 33179413
doi: 10.1002/1878-0261.12851
pmcid: 7718954
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8:e000337.
pubmed: 32209603
doi: 10.1136/jitc-2019-000337
pmcid: 7064135
Kepp O, Bezu L, Yamazaki T, Di Virgilio F, Smyth MJ, Kroemer G, et al. ATP and cancer immunosurveillance. EMBO J. 2021;40:e108130.
pubmed: 34121201
doi: 10.15252/embj.2021108130
pmcid: 8246257
Poon CC, Sarkar S, Yong VW, Kelly JJP. Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis. Brain. 2017;140:1548–60.
pubmed: 28334886
doi: 10.1093/brain/aww355
Kvisten M, Mikkelsen VE, Stensjøen AL, Solheim O, Van Der Want J, Torp SH. Microglia and macrophages in human glioblastomas: a morphological and immunohistochemical study. Mol Clin Oncol. 2019;11:31–6.
pubmed: 31289674
pmcid: 6535640
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321–30.
pubmed: 28102259
doi: 10.1038/nature21349
Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30:36–50.
pubmed: 31269428
doi: 10.1016/j.cmet.2019.06.001
Peters C, Paget M, Tshilenge K-T, Saha D, Antoszczyk S, Baars A, et al. Restriction of replication of oncolytic herpes simplex virus with a deletion of γ34.5 in glioblastoma stem-like cells. J Virol. 2018;92:e00246–18.
pubmed: 29793956
doi: 10.1128/JVI.00246-18
pmcid: 6052301
Delwar ZM, Kuo Y, Wen YH, Rennie PS, Jia W. Oncolytic virotherapy blockade by microglia and macrophages requires STAT1/3. Cancer Res. 2018;78:718–30.
pubmed: 29118089
doi: 10.1158/0008-5472.CAN-17-0599
Nakashima H, Nguyen T, Kasai K, Passaro C, Ito H, Goins WF, et al. Toxicity and efficacy of a novel GADD34-expressing oncolytic HSV-1 for the treatment of experimental glioblastoma. Clin Cancer Res. 2018;24:2574–84.
pubmed: 29511029
doi: 10.1158/1078-0432.CCR-17-2954
pmcid: 6800093
Zhang Z, Yang N, Xu L, Lu H, Chen Y, Wang Z, et al. Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy. Cancer Immunol Immunother. 2024;73:173.
pubmed: 38953982
doi: 10.1007/s00262-024-03757-8
pmcid: 11219689
Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X, et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol Ther. 2023;31:134–53.
pubmed: 36056553
doi: 10.1016/j.ymthe.2022.08.021
Sun Y, Zhang Z, Zhang C, Zhang N, Wang P, Chu Y, et al. An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition. Mol Ther Oncolytics. 2022;26:105–19.
pubmed: 35795092
doi: 10.1016/j.omto.2022.05.008
pmcid: 9233193
Tang G, Wang D, Zhao X, Feng Z, Chen Q, Shen Y. The dilemma of HSV-1 oncolytic virus delivery: the method choice and hurdles. Int J Mol Sci. 2023;24:3681.
pubmed: 36835091
doi: 10.3390/ijms24043681
pmcid: 9962028
Zhang S, Zhang S, Luo S, Tang P, Wan M, Wu D, et al. Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: advance and prospect. J Nanobiotechnol. 2022;20:287.
doi: 10.1186/s12951-022-01464-z
Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T cells and human disease. Annu Rev Immunol. 2020;38:541–66.
pubmed: 32017635
doi: 10.1146/annurev-immunol-042718-041717
van den Bossche WBL, Kleijn A, Teunissen CE, Voerman JSA, Teodosio C, Noske DP, et al. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. Neuro Oncol. 2018;20:1494–504.
pubmed: 29796615
doi: 10.1093/neuonc/noy082
pmcid: 6176807
Meazza R, Comes A, Orengo AM, Ferrini S, Accolla RS. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur J Immunol. 2003;33:1183–92.
pubmed: 12731043
doi: 10.1002/eji.200323712
Frangione V, Mortara L, Castellani P, De Lerma Barbaro A, Accolla RS. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4 + T lymphocytes for immunotherapy. Int J Cancer. 2010;127:1614–24.
pubmed: 20091859
doi: 10.1002/ijc.25183
Bou Nasser Eddine F, Forlani G, Lombardo L, Tedeschi A, Tosi G, Accolla RS. CIITA-driven MHC class II expressing tumor cells can efficiently prime naive CD4 + TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells. Oncoimmunology. 2017;6:e1261777.
pubmed: 28197387
doi: 10.1080/2162402X.2016.1261777